Lucid Diagnostics Inc.

LUCD
$1.11 (+ $0.04 + 3.74%)
Last updated: 2026-05-27 02:48 UTC
LUCD Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryMedical Devices
ISINUS54948X1090
CUSIP54948X109
Market Price1.11
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.77
Market Cap$145.5M
Book Value-0.23
Price to Book-4.847
Beta1.23
52w High1.8
52w Low0.75
Next Earnings DateN/A

Lucid Diagnostics Inc. trades under ticker LUCD on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US54948X1090, CUSIP 54948X109.

About the Company
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Price History